Indications for: MINOLIRA
Inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Swallow whole. Give approximately 1mg/kg once daily for 12wks. Weight-based dosing (45–59kg): 52.5mg; (60–89kg): 67.5mg; (90–125kg): 105mg; (126–136kg): 135mg. Renal impairment: reduce dose or extend dosing intervals.
<12yrs: not established.
Monitor blood, renal, and hepatic function periodically. Discontinue if skin erythema, DRESS syndrome, or superinfection develops. Overweight women. History of intracranial hypertension. Monitor for visual disturbances. Renal or hepatic impairment. Avoid sun or UV light. Pregnancy, nursing mothers: not recommended.
Avoid concomitant penicillins, isotretinoin. Fatal renal toxicity with concomitant methoxyflurane. May need to reduce concomitant anticoagulant dose. Absorption reduced by antacids containing aluminum, calcium, magnesium and iron. May antagonize oral contraceptives. May interfere with fluorescence test.
Headache, fatigue, dizziness, pruritus, malaise; teeth discoloration, delayed skeletal development, intracranial hypertension, CNS effects, C.difficile-associated diarrhea, photosensitivity, increased BUN, hepatotoxicity, renal toxicity, hyperpigmentation, skin/hypersensitivity reactions (may be severe), lupus-like syndrome, serum sickness-like syndrome.
Generic Drug Availability: